What happened Shares of Sunesis Pharmaceuticals (SNSS) are sinking today, down 10.4% as of 11:35 a.m. EDT after falling as much as 19.3% earlier in the session. The decline stemmed from the company's announcement on Wednesday evening that it planned to conduct a 1-for-10 reverse stock split.
Is SNSs stock headed to $12?
Apr 03, 2022 · Source Headline; 4 Stocks Under $10 to Trade Now thestreet.com - January 14 at 10:56 PM: Sunesis Pharmaceuticals, Inc. (SNSS) nasdaq.com - July 15 at 10:45 PM
Is Sunesis Pharmaceuticals (SNSs) stock headed to $12?
Feb 23, 2021 · This is why it happened. The stock price of Sunesis Pharmaceuticals, Inc (NASDAQ: SNSS) increased by over 46% during intraday trading as it went from a previous close of $3.56 to a day high of $5.20. One of the biggest triggers for the stock price increase has to do with a bullish research report from a brokerage.
Why is Sunesis’ stock trending up?
Feb 23, 2021 · Sunesis Pharmaceuticals (NASDAQ: SNSS) is up more than 20% in trading today after analysts at Oppenheimer upgraded the stock to “outperform.” Those analysts set a price target for SNSS stock ...
How much do you trade SNSs each day?
Apr 01, 2022 · Friday, 1st Apr 2022 SNSS stock ended at $5.32. During the day the stock fluctuated 0% from a day low at $5.32 to a day high of $5.32. 90 …
What happened to Snss?
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS").Feb 24, 2021
What happened sunesis pharmaceuticals?
Sunesis Pharma shares jumped on Monday after the biopharma agreed to merge into Viracta Therapeutics, a closely held oncology company. Sunesis Pharmaceuticals (SNSS) - Get Sunesis Pharmaceuticals, Inc.Nov 30, 2020
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its quarterly earnings results on Sunday, November, 15th. The biopharmaceutical company reported...
When did Sunesis Pharmaceuticals' stock split? How did Sunesis Pharmaceuticals' stock split work?
Sunesis Pharmaceuticals's stock reverse split on the morning of Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, Se...
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the following people: Dr. Judith A. Fox , Chief Scientific Officer and Exec. VP of R&D (Age 64...
What is Dan Swisher Jr.'s approval rating as Sunesis Pharmaceuticals' CEO?
4 employees have rated Sunesis Pharmaceuticals CEO Dan Swisher Jr. on Glassdoor.com . Dan Swisher Jr. has an approval rating of 82% among Sunesis...
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Amgen (AMGN) , Regeneron Pharmaceuticals (REGN) , Gilead Sciences (GILD) , V...
What other stocks do shareholders of Sunesis Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include (SLS) , Am...
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How much money does Sunesis Pharmaceuticals make?
Sunesis Pharmaceuticals has a market capitalization of $0.00 and generates $2.07 million in revenue each year. The biopharmaceutical company earns...
How many employees does Sunesis Pharmaceuticals have?
Sunesis Pharmaceuticals employs 24 workers across the globe.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers.
Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock.